CSLCSLLY -2.30%73 PEG Ratio is 2.06 as of Jun. 27, 2026, which is 25% below its 10-year median of 2.73. GuruFocus rates CSLLY with a GF Score™ of 73/100 and a GF Value™ of $50.49 (Significantly Undervalued). The stock has 7 warning signs investors should review. Among 95 Biotechnology companies, CSL ranks worse than 52.63% on this metric.
PE Ratio without NRI / 5-Year EBITDA Growth Rate*
PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, CSL's PE Ratio without NRI is 22.25. CSL's 5-Year EBITDA growth rate is 10.80%. Therefore, CSL's PEG Ratio for today is 2.06.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for CSL's PEG Ratio or its related term are showing as below:
CSLLY'
s PEG Ratio Range Over the Past 10 Years
Min: 0.94 Med: 2.73 Max: 6.01
Current: 2.06
During the past 13 years, CSL's highest PEG Ratio was 6.01. The lowest was 0.94. And the median was 2.73.
CSLLY's PEG Ratio is ranked worse than 52.63% of 95
companies
in the Biotechnology industry
Industry Median: 1.92
vs CSLLY: 2.06
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
CSL (OTCPK:CSLLY) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
CSL PEG Ratio Related Terms
CSL PEG Ratio Historical Data
* Premium members only.
The historical data trend for CSL's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, CSL's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CSL PEG Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CSL's PEG Ratio distribution charts can be found below:
* The bar in red indicates where CSL's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
CSL (CSLLY) has a PEG Ratio of 2.06 as of Jun. 27, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on CSL and its competitors. This is 25% below median its historical median of 2.73. Over the past decade, CSL's PEG Ratio has ranged from 0.94 to 6.01. According to the industry distribution chart, CSL ranks #50 out of 95 companies in the Biotechnology industry, placing it in the top 52.6%.
Is CSL's PEG Ratio too high?
CSL's current PEG Ratio of 2.06 is 25% below median its 10-year median of 2.73. Over the past 10 years, this metric has ranged from a low of 0.94 to a high of 6.01. The Biotechnology industry median PEG Ratio is 1.92. CSL's value of 2.06 is 7.3% above this industry median. Based on the distribution chart, CSL ranks #50 out of 95 companies in the Biotechnology industry, which is below the industry midpoint. Overall, CSL has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CSL's PEG Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CSL ranks #50 out of 95 companies for PEG Ratio. This places CSL in the lower half of its industry. The industry median PEG Ratio is 1.92. CSL's value of 2.06 is 7.3% above this benchmark. Historically, CSL's own PEG Ratio has ranged from 0.94 to 6.01 over the past decade. While the company's 10-year median is 2.73 vs. the industry median of 1.92, CSL has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Biotechnology company?
The median PEG Ratio among Biotechnology companies is 1.92, based on 95 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CSL's current PEG Ratio of 2.06 is 7.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on CSL and its competitors. For the Biotechnology industry, the median PEG Ratio is 1.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CSL's current PEG Ratio is 2.06, which is 25% below median its own 10-year median of 2.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CSL stock overvalued right now?
Based on GuruFocus' analysis, CSL (CSLLY) is currently considered Significantly Undervalued. The stock's GF Value™ is $50.49, compared to a current price of $19.98 — trading 60.4% below its estimated fair value. The current PEG Ratio is 2.06, which is 25% below median its 10-year median of 2.73 and 7.3% above the Biotechnology industry median of 1.92. CSL's overall GF Score™ is 73/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For CSL (CSLLY), the current PEG Ratio is 2.06 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CSL (CSLLY) Overvalued in 2026?
Based on GuruFocus' analysis, CSL stock appears to be undervalued.
The current stock price of $19.98 is trading 60.4% below its estimated GF Value™ of $50.49.
GuruFocus considers CSL to be Significantly Undervalued.
Key valuation signals for CSLLY:
PEG Ratio: 2.06 (25% below median its 10-year median of 2.73)
GF Value™: $50.49 vs. price of $19.98 (60.4% below fair value)
Industry Position: 7.3% above the Biotechnology median (#50 of 95)
No single metric tells the full story. See the CSLLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CSL is one of the largest global biotech companies and has three main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world's second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.
73GF Score
Get the complete analysis for CSLLY
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSLLY has been successfully added to your 
